Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Pfizer
Josep Tabernero; Axel Grothey; Eric Van Cutsem; Rona Yaeger; Harpreet Wasan; Takayuki Yoshino; Jayesh Desai; Fortunato Ciardiello; Fotios Loupakis; Yong Sang Hong; Neeltje Steeghs; Tormod Kyrre Guren; Hendrik-Tobias Arkenau; Pilar Garcia-Alfonso; Elena Elez; Ashwin Gollerkeri; Kati Maharry; Janna Christy-Bittel; Scott Kopetz